Idex forecasts 2026 adjusted EPS of $8.35-$8.55 as it lifts organic growth outlook to 3%-4% (NYSE:IEX)

Earnings Call Insights: IDEX Corporation (IEX) Q1 2026 Management view * "IDEX delivered a strong first quarter" with "organic sales growth of 5% and adjusted EBITDA margin of 26%" and "orders were better than expected, growing 10% organically year-over-year" (CEO, President & Director Eric Ashleman). This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. IDEX raised 2026 organic growth guidance to 3%-4% (from 1%-2%), increased adjusted EPS to $8.35-$8.55 (from $8.15-$8.35), while keeping adjusted EBITDA margin at 26.5%-27%. Risks include life sciences demand headwinds from the China market and NIH funding, ongoing macro and geopolitical uncertainty affecting short-cycle and industrial end markets, especially chemicals and energy exposures. Management cites strong HST organic order growth and backlog build, providing better visibility to deliver solid growth for the rest of the year and into 2027.